Pharmacokinetic Alterations Associated with Critical Illness.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 209, doi. 10.1007/s40262-023-01213-x
- By:
- Publication type:
- Article
Works matching IS 03125963 AND DT 2023 AND VI 62 AND IP 2
Results: 11
1
2
Correction to: Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
3
Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 157, doi. 10.1007/s40262-023-01212-y
- By:
- Publication type:
- Article
4
Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part I—Penicillins.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 221, doi. 10.1007/s40262-023-01211-z
- By:
- Publication type:
- Article
5
Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 307, doi. 10.1007/s40262-022-01205-3
- By:
- Publication type:
- Article
6
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 321, doi. 10.1007/s40262-022-01203-5
- By:
- Publication type:
- Article
7
Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 297, doi. 10.1007/s40262-022-01202-6
- By:
- Publication type:
- Article
8
Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 335, doi. 10.1007/s40262-022-01199-y
- By:
- Publication type:
- Article
9
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 277, doi. 10.1007/s40262-022-01194-3
- By:
- Publication type:
- Article
10
Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 249, doi. 10.1007/s40262-022-01193-4
- By:
- Publication type:
- Article
11
Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 267, doi. 10.1007/s40262-022-01192-5
- By:
- Publication type:
- Article